Program

Tuesday, 7 September 2021

08:00 Registration opens 
09:00-17:00 Exhibition throughout the day
Foyer 2nd Floor

Booth 1: Swiss Biotech Association
Booth 2: Supporting Partners
Booth 3: Fluidair division of SSCO-Spraying Systems AG
Booth 4: GenScript
Booth 5: BakerHicks AG
Booth 6: Spinofrin
Booth 7: Hamilton Bonaduz
Booth 8: VectorBuilder GmbH
Booth 9: Benchling Switzerland GmbH
Booth 9a: PALL International Sàrl
Booth 10: Kneat Solutions Ltd.
Booth 11: SFL Regulatory Affairs & Scientific Communication GmbH
Booth 12: InnoMedica Holding AG
Booth 13: Eurofins Genomics Germany GmbH
Booth 13a: Eurofins CDMO
Booth 14: IQVIA
Booth 14a: VectorB2B
Booth 15: Innosuisse
Booth 16: Thermo Fisher Scientific
Booth 17: Senn Development AG
Booth 18: ASEBIO
Booth 19: Marken
Booth 20: Yumab GmbH
Booth 21: KLIFO GmbH
Booth 22: AnaPath Services GmbH
Booth 23: BioRN Cluster Management GmbH
Booth 24: CRB Group GmbH
Booth 25: Eurogentec
Booth 26: PCI
Booth 27: PHARMAPLAN AG
Booth 28: Tigermed Swiss AG
Booth 29: SIX
Booth 30: Protagen Protein Services GmbH
Booth 31: MLM Medical Labs GmbH
Booth 32: Jakob AG Prozesstechnik
Booth 33: B Medical System S.a.r.l.
Booth 33a: Sanisure
Booth 34: Connectiv Relocation AG
Booth 35: SCBio
Booth 36: VTU Engineering Schweiz AG
Booth 37: Premier Research International LLC
Booth 38: HBIO Hellenic Bio Cluster
Booth 39: KNAUER Wissenshcaftliche Geräte GmbH
Booth 40: KBI Biopharma

Booth 1: Swiss Biotech Association
Booth 2: Supporting Partners
Booth 3: Fluidair division of SSCO-Spraying Systems AG
Booth 4: GenScript
Booth 5: BakerHicks AG
Booth 6: Spinofrin
Booth 7: Hamilton Bonaduz
Booth 8: VectorBuilder GmbH
Booth 9: Benchling Switzerland GmbH
Booth 9a: PALL International Sàrl
Booth 10: Kneat Solutions Ltd.
Booth 11: SFL Regulatory Affairs & Scientific Communication GmbH
Booth 12: InnoMedica Holding AG
Booth 13: Eurofins Genomics Germany GmbH
Booth 13a: Eurofins CDMO
Booth 14: IQVIA
Booth 14a: VectorB2B
Booth 15: Innosuisse
Booth 16: Thermo Fisher Scientific
Booth 17: Senn Development AG
Booth 18: ASEBIO
Booth 19: Marken
Booth 20: Yumab GmbH
Booth 21: KLIFO GmbH
Booth 22: AnaPath Services GmbH
Booth 23: BioRN Cluster Management GmbH
Booth 24: CRB Group GmbH
Booth 25: Eurogentec
Booth 26: PCI
Booth 27: PHARMAPLAN AG
Booth 28: Tigermed Swiss AG
Booth 29: SIX
Booth 30: Protagen Protein Services GmbH
Booth 31: MLM Medical Labs GmbH
Booth 32: Jakob AG Prozesstechnik
Booth 33: B Medical System S.a.r.l.
Booth 33a: Sanisure
Booth 34: Connectiv Relocation AG
Booth 35: SCBio
Booth 36: VTU Engineering Schweiz AG
Booth 37: Premier Research International LLC
Booth 38: HBIO Hellenic Bio Cluster
Booth 39: KNAUER Wissenshcaftliche Geräte GmbH
Booth 40: KBI Biopharma

09:00-17:00 Partnering throughout the day
Room San Francisco
09:00-17:00 Corporate Rooms
09:00-17:00 Room Hongkong
presented by PMI
Partner companies:

CSEM is a private non-profit Swiss organization for research and innovation. Supported by the Swiss Confederation, our mission is to enhance the competitiveness of industry by narrowing the gap between fundamental research and industrialization. By expanding CSEM’s knowledge and adapting it to industrial needs, new products are brought to market. CSEM works with partners active in industrial sectors such as life science, watchmaking, or space.

InSphero is a Swiss-based phenomics biotech that has been perfecting 3D-cell-based drug discovery platforms and scaffold-free 3D OoC technologies for more than 10 years. InSphero deploys its patent-pending technologies for highly scalable drug discovery programs against liver diseases, e.g NASH and NAFLD, T1 and T2 diabetes, and solid cancers, as well as for Safety testing with the market leading 3D InSight™ Liver Toxicology platform.

TissUse is a Berlin, Germany-based, biotechnology company who has developed a unique HUMIMIC Multi-Organ-Chip platform for advanced toxicity testing and cutting-edge disease modelling.

Epithelix is a Swiss biotech, leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. Epithelix has developed unique 3D in vitro human airway tissues and testing services for studying airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases, Bacterial and Viral infections.

09:00-17:00 Room Guangzhou
presented by Sintetica

Sintetica is a privately held international pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions in ampoules, vials and IV bags for hospitals. Sintetica develops medicines in concentrated and premixed formulations, enabling HCPs to administer these products without manipulation and dilution, increasing safety and improving convenience. For more information about Sintetica, please visit the corporate website, sintetica.com.

09:00-17:00 Room Hongkong
presented by PMI
Partner companies:

CSEM is a private non-profit Swiss organization for research and innovation. Supported by the Swiss Confederation, our mission is to enhance the competitiveness of industry by narrowing the gap between fundamental research and industrialization. By expanding CSEM’s knowledge and adapting it to industrial needs, new products are brought to market. CSEM works with partners active in industrial sectors such as life science, watchmaking, or space.

InSphero is a Swiss-based phenomics biotech that has been perfecting 3D-cell-based drug discovery platforms and scaffold-free 3D OoC technologies for more than 10 years. InSphero deploys its patent-pending technologies for highly scalable drug discovery programs against liver diseases, e.g NASH and NAFLD, T1 and T2 diabetes, and solid cancers, as well as for Safety testing with the market leading 3D InSight™ Liver Toxicology platform.

TissUse is a Berlin, Germany-based, biotechnology company who has developed a unique HUMIMIC Multi-Organ-Chip platform for advanced toxicity testing and cutting-edge disease modelling.

Epithelix is a Swiss biotech, leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. Epithelix has developed unique 3D in vitro human airway tissues and testing services for studying airway pathologies like Asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases, Bacterial and Viral infections.

09:00-17:00 Room Guangzhou
presented by Sintetica

Sintetica is a privately held international pharmaceutical company focused on analgesics, local anesthetics and sterile injectable solutions in ampoules, vials and IV bags for hospitals. Sintetica develops medicines in concentrated and premixed formulations, enabling HCPs to administer these products without manipulation and dilution, increasing safety and improving convenience. For more information about Sintetica, please visit the corporate website, sintetica.com.

09:00 Press Conference
Room Sydney
09:30-12:00 Plenary Session
Room Montreal

Moderator: Monika Jones

09:30 Welcome Address
Michael Altorfer, CEO, Swiss Biotech Association
09:35 Covid quo vadis
Patrick Amstutz, CEO, Molecular Partners
Filippo Riva, Managing Director, Humabs Biomed, a subsidiary of Vir Biotechnology

Teresa Graham, Head Global Product Strategy, Roche
Prof. Dr. med. Hans H. Hirsch, MSc, Senior physician Immunology and Infectious Diseases, University Hospital Basel
10:05 Manufacturing of novel biotherapeutics: the next Eldorado for Switzerland?
Patrick Aebischer, entrepreneur and former EPFL President
10:15 Follow up panel discussion
Patrick Aebischer, entrepreneur and former EPFL President
Albert Bähny, Chairman, Lonza
Konstantin Matentzoglu, CEO, Celonic
Raymond De Vré, CEO, PolyPeptide Laboratories (PPL)
Thomas Meier, CEO, Bachem
10:45 Update on Swiss Biotech Report
Jürg Zürcher, Expert and EY Senior Advisor in the field of Biotechnology, EY
10:55 Highlights from European Site Selection report
André Güdel, International Business Development, Global Location and Site Analyst, KPMG AG
11:00 Development of recombinant human antibodies as therapeutics
Roger Nitsch, CEO, Neurimmune
11:25 Swiss Biotech Success Stories Award
11:55 Closing remarks
Michael Altorfer, CEO, Swiss Biotech Association

Moderator: Monika Jones

09:30 Welcome Address
Michael Altorfer, CEO, Swiss Biotech Association
09:35 Covid quo vadis
Patrick Amstutz, CEO, Molecular Partners
Filippo Riva, Managing Director, Humabs Biomed, a subsidiary of Vir Biotechnology

Teresa Graham, Head Global Product Strategy, Roche
Prof. Dr. med. Hans H. Hirsch, MSc, Senior physician Immunology and Infectious Diseases, University Hospital Basel
10:05 Manufacturing of novel biotherapeutics: the next Eldorado for Switzerland?
Patrick Aebischer, entrepreneur and former EPFL President
10:15 Follow up panel discussion
Patrick Aebischer, entrepreneur and former EPFL President
Albert Bähny, Chairman, Lonza
Konstantin Matentzoglu, CEO, Celonic
Raymond De Vré, CEO, PolyPeptide Laboratories (PPL)
Thomas Meier, CEO, Bachem
10:45 Update on Swiss Biotech Report
Jürg Zürcher, Expert and EY Senior Advisor in the field of Biotechnology, EY
10:55 Highlights from European Site Selection report
André Güdel, International Business Development, Global Location and Site Analyst, KPMG AG
11:00 Development of recombinant human antibodies as therapeutics
Roger Nitsch, CEO, Neurimmune
11:25 Swiss Biotech Success Stories Award
11:55 Closing remarks
Michael Altorfer, CEO, Swiss Biotech Association
12:00 Lunch
13:00-17:00 Parallel Tracks

Moderation: Dr. Dominik Escher & Dr. Martin Münchbach, Pureos Bioventures

13:00

13:10

13:20

13:30

13:40

13:50

14:00

14:10

14:20

14:30

14:40

14:50

15:00

15:10

15:20

15:30

15:40

15:50

16:00

16:10

16:20

16:30

16:40

Pureos Bioventures

EraCal Therapeutics AG

Acthera Therapeutics

Alentis Therapeutics

Araris Biotech

Avrion Therapeutics

BioLingus

CanVirex

Cellvie AG

Gnubiotics Science SA

GlycoEra

Haya Therapeutics

– short break –

Immunophotonics Switzerland

Muvon Therapeutics

MV BioTherapeutics SA

Nouscom

NovaGo Therapeutics

Perseo Pharma

Saverna

Stalicla

Vaderis Therapeutics

Deep Breath Intelligence

presented by Pureos Bioventures

12:15-13:45 Panel 1: Swiss-Sino Biotech Forum: Innovation and Investment
Moderators:

  • Prof. Dr. Minyue Dong Director of China Economics and Finance Center (CEFC) Director of Department of Accounting and Control HEC – University of Lausanne
  • Ms. Jing Chen (online) CEO of Shanghai BioBridge Biotechnology

Speaker:

  • Ms. Victoria YOU, Representative of Zhangjiagang High-tech Zone
  • Dr. WEN Hong, Partner, Shanghai Biomedical Fund
  • Dr. ZHOU Hao, Partner, DHLT Investment
  • Mr. FAN Yin, Co-founder & General Manager, GP Capital (Healthcare Division)
  • Mr. LIU Gang, General Secretary, Pudong Biotechnology Association
  • Mr. GAO Lingyun, Chairman, Hong Yi Investment, Visiting Scholar of Stanford University
  • Mr. YUAN Fei, General Manager, The Oriental Beauty Valley Group

Short summary:
The panel showcases biotech innovation and life science ecosystem in China by presenting major biotech parks and enterprises. It also holds a dialogue between Chinese and Swiss financial institutions and technology startups to share their insights on investment and enterprise development in life science fields. Overall, the panel aims to foster interaction among researchers, companies and investors in China and Switzerland and enhance biotech cooperation between the two countries.

presented by CEFC

14:00-14:45 Panel 2: Is Switzerland still attractive for manufacturing and R&D projects in Life Sciences?
Moderator: Monika Jones
Speaker:

  • Patrik Frei, Founder and CEO at Venture Valuation AG
  • Jean-Christophe Hyvert, President Biologics Division and Cell and Gene Bioscence Division at Lonza AG
  • Michael Hübner, Director Early Innovation Partnering, Johnson&Johnson
  • André Guedel, International Business Development, Global Location and Site Analyst at KPMG AG

Short summary:
There is a resurgence of industrial strategies across Europe and Life Sciences is at the core of these efforts. Countries are competing fiercely to attract manufacturing and R&D projects. How is Switzerland positioned in the race to attract the most interesting projects? Industry representatives and site selection experts will discuss the latest trends and how they affect Switzerland’s Life Sciences landscape.

presented by KPMG
15:00-15:45 Panel 3: Synthesis of Therapeutic Peptides via Microbial Chemistry with Recombinant DNA Technology. A Green Strategy for Future Application to the Early Phase Development.

Moderator: Monika Jones
Speaker:

  • Giorgio Bertolini, Research and Development Vice President, Olon Group
  • Antonella Malcangi, Research and Development Manager Olon Group

Short summary:
Olon Biotechnology Centers represent one of the most extensive know how of microbial fermentation in Europe. The Recombinant DNA Technology is a powerful method for engineering organisms with new specific capabilities, it represents a promising solution to problems of availability of natural resources. Olon has developed a very efficient purification process thanks to the affinity tag, offering high quality peptides.

presented by Olon S.p.A.
16:00-16:45 Panel 4: Artificial intelligence, machine learning and automation – impact in life sciences today and in the future
Moderator: Axel Nemetz, Digital Health Venture Capital Investor
Speaker:

  • Adham Kassab, International Business Leader Personal Digital Solutions at mySugr/Roche
  • Bram Stieltjes, Department Head Research and Analytic Services at Universitätsspital Basel
  • Cédric Weber, Co-founder deepCDR
  • Souvik Sengupta, Vice President Analytics and Digital Transformation at IQVIA

Short summary:
Everyone is talking about AI, ML and automation. But which use cases are already adding value to the various players in the life sciences and healthcare industry today? Panelists will provide unvarnished insights, share what’s next and where they see the biggest hurdles. They will share insights from the hospital, biotech, pharma, diagnostics and specialized management consulting industries. Questions from the audience are welcome to allow for an interactive, insightful panel discussion.

12:30-12:55 Venture Leaders Biotech 2021
Moderation: Jordi Montserrat, Co-Founder and Managing Partner, Venturelab

Companies:

Stalicla, NextImmune, deepCDR Biologics, Cellvie, Gnubiotics Sciences, Avrion Therapeutics, Acthera Therapeutics, HexagonFab, Alithea Genomics, Nemosia

Short summary:
The Venture Leaders – as members of the Swiss National Startup Team – have a clear-cut goal. They envision themselves as global players and want to fuel their global expansion in the biotech industry. Join the biotech team’s introduction and pitch session and vote for the Team Captain for their roadshow to Boston in the United States.

Emerging Biotech Companies – Technologies

Moderation: Dr. Klaus Breiner & Dr. Ximing Ding, Pureos Bioventures

13:00

13:10

13:20

13:30

13:40

13:50

14:00

14:15

14:25

14:35

14:45

14:55

Pureos Bioventures

ABCDx

Adiposs

Alithea Genomics

deepCDR Biologics

Limula Biotech

Lino Biotech

Nagi Bioscience

Resistell

Scailyte

SpacePharma

Superlab Suisse

15:15-16:00 Panel 5: Financing Swiss Biotech Innovation
Moderator: Lorenzo Leoni, Tiventure
Speaker:

  • Fabio Napoletano, Head BD, Swiss Biotech Association
  • Fabian Gerber, Senior Relationship Manager Primary Markets, SIX Group
  • Dr Nicole Wyss, National Contact Point for Health, Euresearch

Short summary:
What partners, instruments and platforms support Swiss biotech companies in funding the development of innovative technologies and medicine.

16:15-17:00 Panel 6: Prepare for success: Pitfalls and tips for the legal, tax, audit and private finance framework.
Moderator: Matthias Staehelin, Lead Partner Life Sciences, VISCHER AG
Speaker:

  • Dieter Gericke, Head Corporate / M&A, Co-Head Healthcare, Homburger AG
  • Tobias Meyer, Partner IPO & Transaction Accounting, Ernst & Young Ltd
  • Maurus Winzap, Certified Tax Expert, Partner Walder Wyss Ltd.

Short summary:
Which elements in the audit, tax and legal framework are challenges, which ones are competitive advantages and what should be optimized.

Moderation: Dr. Dominik Escher & Dr. Martin Münchbach, Pureos Bioventures

13:00

13:10

13:20

13:30

13:40

13:50

14:00

14:10

14:20

14:30

14:40

14:50

15:00

15:10

15:20

15:30

15:40

15:50

16:00

16:10

16:20

16:30

16:40

Pureos Bioventures

EraCal Therapeutics AG

Acthera Therapeutics

Alentis Therapeutics

Araris Biotech

Avrion Therapeutics

BioLingus

CanVirex

Cellvie AG

Gnubiotics Science SA

GlycoEra

Haya Therapeutics

– short break –

Immunophotonics Switzerland

Muvon Therapeutics

MV BioTherapeutics SA

Nouscom

NovaGo Therapeutics

Perseo Pharma

Saverna

Stalicla

Vaderis Therapeutics

Deep Breath Intelligence

presented by Pureos Bioventures

12:15-13:45 Panel 1: Swiss-Sino Biotech Forum: Innovation and Investment
Moderators:

  • Prof. Dr. Minyue Dong Director of China Economics and Finance Center (CEFC) Director of Department of Accounting and Control HEC – University of Lausanne
  • Ms. Jing Chen (online) CEO of Shanghai BioBridge Biotechnology

Speaker:

  • Ms. Victoria YOU, Representative of Zhangjiagang High-tech Zone
  • Dr. WEN Hong, Partner, Shanghai Biomedical Fund
  • Dr. ZHOU Hao, Partner, DHLT Investment
  • Mr. FAN Yin, Co-founder & General Manager, GP Capital (Healthcare Division)
  • Mr. LIU Gang, General Secretary, Pudong Biotechnology Association
  • Mr. GAO Lingyun, Chairman, Hong Yi Investment, Visiting Scholar of Stanford University
  • Mr. YUAN Fei, General Manager, The Oriental Beauty Valley Group

Short summary:
The panel showcases biotech innovation and life science ecosystem in China by presenting major biotech parks and enterprises. It also holds a dialogue between Chinese and Swiss financial institutions and technology startups to share their insights on investment and enterprise development in life science fields. Overall, the panel aims to foster interaction among researchers, companies and investors in China and Switzerland and enhance biotech cooperation between the two countries.

presented by CEFC

14:00-14:45 Panel 2: Is Switzerland still attractive for manufacturing and R&D projects in Life Sciences?
Moderator: Monika Jones
Speaker:

  • Patrik Frei, Founder and CEO at Venture Valuation AG
  • Jean-Christophe Hyvert, President Biologics Division and Cell and Gene Bioscence Division at Lonza AG
  • Michael Hübner, Director Early Innovation Partnering, Johnson&Johnson
  • André Guedel, International Business Development, Global Location and Site Analyst at KPMG AG

Short summary:
There is a resurgence of industrial strategies across Europe and Life Sciences is at the core of these efforts. Countries are competing fiercely to attract manufacturing and R&D projects. How is Switzerland positioned in the race to attract the most interesting projects? Industry representatives and site selection experts will discuss the latest trends and how they affect Switzerland’s Life Sciences landscape.

presented by KPMG
15:00-15:45 Panel 3: Synthesis of Therapeutic Peptides via Microbial Chemistry with Recombinant DNA Technology. A Green Strategy for Future Application to the Early Phase Development.

Moderator: Monika Jones
Speaker:

  • Giorgio Bertolini, Research and Development Vice President, Olon Group
  • Antonella Malcangi, Research and Development Manager Olon Group

Short summary:
Olon Biotechnology Centers represent one of the most extensive know how of microbial fermentation in Europe. The Recombinant DNA Technology is a powerful method for engineering organisms with new specific capabilities, it represents a promising solution to problems of availability of natural resources. Olon has developed a very efficient purification process thanks to the affinity tag, offering high quality peptides.

presented by Olon S.p.A.
16:00-16:45 Panel 4: Artificial intelligence, machine learning and automation – impact in life sciences today and in the future
Moderator: Axel Nemetz, Digital Health Venture Capital Investor
Speaker:

  • Adham Kassab, International Business Leader Personal Digital Solutions at mySugr/Roche
  • Bram Stieltjes, Department Head Research and Analytic Services at Universitätsspital Basel
  • Cédric Weber, Co-founder deepCDR
  • Souvik Sengupta, Vice President Analytics and Digital Transformation at IQVIA

Short summary:
Everyone is talking about AI, ML and automation. But which use cases are already adding value to the various players in the life sciences and healthcare industry today? Panelists will provide unvarnished insights, share what’s next and where they see the biggest hurdles. They will share insights from the hospital, biotech, pharma, diagnostics and specialized management consulting industries. Questions from the audience are welcome to allow for an interactive, insightful panel discussion.

12:30-12:55 Venture Leaders Biotech 2021
Moderation: Jordi Montserrat, Co-Founder and Managing Partner, VenturelabCompanies:

Stalicla, NextImmune, deepCDR Biologics, Cellvie, Gnubiotics Sciences, Avrion Therapeutics, Acthera Therapeutics, HexagonFab, Alithea Genomics, Nemosia

Short summary:
The Venture Leaders – as members of the Swiss National Startup Team – have a clear-cut goal. They envision themselves as global players and want to fuel their global expansion in the biotech industry. Join the biotech team’s introduction and pitch session and vote for the Team Captain for their roadshow to Boston in the United States.

Emerging Biotech Companies – Technologies

Moderation: Dr. Klaus Breiner & Dr. Ximing Ding, Pureos Bioventures

13:00

13:10

13:20

13:30

13:40

13:50

14:00

14:15

14:25

14:35

14:45

14:55

Pureos Bioventures

ABCDx

Adiposs

Alithea Genomics

deepCDR Biologics

Limula Biotech

Lino Biotech

Nagi Bioscience

Resistell

Scailyte

SpacePharma

Superlab Suisse

15:15-16:00 Panel 5: Financing Swiss Biotech Innovation
Moderator: Lorenzo Leoni, Tiventure
Speaker:

  • Fabio Napoletano, Head BD, Swiss Biotech Association
  • Fabian Gerber, Senior Relationship Manager Primary Markets, SIX Group
  • Dr Nicole Wyss, National Contact Point for Health, Euresearch

Short summary:
What partners, instruments and platforms support Swiss biotech companies in funding the development of innovative technologies and medicine.

16:15-17:00 Panel 6: Prepare for success: Pitfalls and tips for the legal, tax, audit and private finance framework.
Moderator: Matthias Staehelin, Lead Partner Life Sciences, VISCHER AG
Speaker:

  • Dieter Gericke, Head Corporate / M&A, Co-Head Healthcare, Homburger AG
  • Tobias Meyer, Partner IPO & Transaction Accounting, Ernst & Young Ltd
  • Maurus Winzap, Certified Tax Expert, Partner Walder Wyss Ltd.

Short summary:
Which elements in the audit, tax and legal framework are challenges, which ones are competitive advantages and what should be optimized.

16:00-18:00 International Reception
Room Rio
Please join us for drinks & networking at the international reception, sponsored by Switzerland Global Enterprise and the UK Department for International Trade at the British Embassy in Bern.

  • Words of welcome by Switzerland Global Enterprise
  • Dr Richard Siow, Director of Ageing Research at King’s College London (KCL) will address the audience with a short talk on the topic of:
    The AgeTech and Healthy Longevity Innovation Landscape: Opportunities for Academic – Industry collaboration


How do we support ageing societies with associated age-related physical and mental health issues?

During the pandemic, shared incentives have enabled health systems and the life sciences industry to work collaboratively in developing vaccines and therapeutics that will enhance healthy ageing and longevity. Looking at this paradigm shift, we need to create partnerships and linkages between industry and the scientific community to respond to these issues.

  • Keynote will be followed by a Q&A session with trade policy expert, Joel Plaja, on the impact of Brexit and the future UK-CH trade agreement.

Profile S-GE

Switzerland Global Enterprise (S-GE) is the official Swiss organization for export and investment promotion with around 200 employees at offices throughout Switzerland and in 31 countries. We support Swiss SMEs in their international business and help innovative foreign companies to establish in Switzerland. In doing so, we rely on a unique network of national and global partners. This is how we create added value for our clients and prosperity for Switzerland. As a non-profit organization, we provide a public service for our clients on behalf of the Swiss Confederation (State Secretariat for Economic Affairs SECO) and the cantons. We operate our 27 offices, known as Swiss Business Hubs and Trade Points, in 31 countries jointly with the Federal Department of Foreign Affairs FDFA. Thanks to our global network of partners, we support our clients in many other countries.


Profile UK Embassy DIT

We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade. We are responsible for delivering 4 priority outcomes:

  1. Secure world-class free trade agreements and reduce market access barriers, ensuring that consumers and businesses can benefit from both.
  2. Deliver economic growth to all the nations and regions of the UK through attracting and retaining inward investment.
  3. Support UK business to take full advantage of trade opportunities, including those arising from delivering free trade agreements (FTAs), facilitating UK exports.
  4. Champion the rules-based international trading system and operate the UK’s new trading system, including protecting UK businesses from unfair trade practices

Please join us for drinks & networking at the international reception, sponsored by Switzerland Global Enterprise and the UK Department for International Trade at the British Embassy in Bern.

  • Words of welcome by Switzerland Global Enterprise
  • Dr Richard Siow, Director of Ageing Research at King’s College London (KCL) will address the audience with a short talk on the topic of:
    The AgeTech and Healthy Longevity Innovation Landscape: Opportunities for Academic – Industry collaboration


How do we support ageing societies with associated age-related physical and mental health issues?

During the pandemic, shared incentives have enabled health systems and the life sciences industry to work collaboratively in developing vaccines and therapeutics that will enhance healthy ageing and longevity. Looking at this paradigm shift, we need to create partnerships and linkages between industry and the scientific community to respond to these issues.

  • Keynote will be followed by a Q&A session with trade policy expert, Joel Plaja, on the impact of Brexit and the future UK-CH trade agreement.

Profile S-GE

Switzerland Global Enterprise (S-GE) is the official Swiss organization for export and investment promotion with around 200 employees at offices throughout Switzerland and in 31 countries. We support Swiss SMEs in their international business and help innovative foreign companies to establish in Switzerland. In doing so, we rely on a unique network of national and global partners. This is how we create added value for our clients and prosperity for Switzerland. As a non-profit organization, we provide a public service for our clients on behalf of the Swiss Confederation (State Secretariat for Economic Affairs SECO) and the cantons. We operate our 27 offices, known as Swiss Business Hubs and Trade Points, in 31 countries jointly with the Federal Department of Foreign Affairs FDFA. Thanks to our global network of partners, we support our clients in many other countries.


Profile UK Embassy DIT

We secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade. We are responsible for delivering 4 priority outcomes:

  1. Secure world-class free trade agreements and reduce market access barriers, ensuring that consumers and businesses can benefit from both.
  2. Deliver economic growth to all the nations and regions of the UK through attracting and retaining inward investment.
  3. Support UK business to take full advantage of trade opportunities, including those arising from delivering free trade agreements (FTAs), facilitating UK exports.
  4. Champion the rules-based international trading system and operate the UK’s new trading system, including protecting UK businesses from unfair trade practices

17:00-19:00 Apéro
Foyer 2nd Floor
19:00 End of the conference

Booth 1:     Swiss Biotech Association
Booth 2:     Supporting Partners
Booth 3:     Fluidair division of SSCO-Spraying Systems AG
Booth 4:     GenScript
Booth 5:     BakerHicks AG
Booth 6:     Spinofrin
Booth 7:     Hamilton Bonaduz
Booth 8:     VectorBuilder GmbH
Booth 9:     Benchling Switzerland GmbH
Booth 9a:   PALL International Sàrl
Booth 10:   Kneat Solutions Ltd.
Booth 11:    SFL Regulatory Affairs & Scientific Communication GmbH
Booth 12:    InnoMedica Holding AG
Booth 13:    Eurofins Genomics Germany GmbH
Booth 13a:  Eurofins CDMO
Booth 14:    IQVIA
Booth 14a:  VectorB2B
Booth 15:    Innosuisse
Booth 16:    Thermo Fisher Scientific
Booth 17:    Senn Development AG
Booth 18:    ASEBIO
Booth 19:    Marken
Booth 20:    Yumab GmbH
Booth 21:    KLIFO GmbH
Booth 22:    AnaPath Services GmbH
Booth 23:    BioRN Cluster Management GmbH
Booth 24:    CRB Group GmbH
Booth 25:    Eurogentec
Booth 26:    PCI
Booth 27:    PHARMAPLAN AG
Booth 28:    Tigermed Swiss AG
Booth 29:    SIX
Booth 30:    Protagen Protein Services GmbH
Booth 31:    MLM Medical Labs GmbH
Booth 32:    Jakob AG Prozesstechnik
Booth 33:    B Medical System S.a.r.l.
Booth 33a:  Sanisure
Booth 34:    Connectiv Relocation AG
Booth 35:    Bright Peak Therapeutics
Booth 36:    VTU Engineering Schweiz AG
Booth 37:    Premier Research International LLC
Booth 38:    HBIO Hellenic Bio Cluster
Booth 39:    KNAUER Wissenshcaftliche Geräte GmbH
Booth 40:    KBI Biopharma